BIOMARIN PHARMACEUTICAL INC, DEF 14A filed on 4/21/2026
Proxy Statement (definitive)
v3.26.1
Cover
 12 Months Ended
Dec. 31, 2025
Document Information [Line Items]  
Document Type DEF 14A
Amendment Flag false
Entity Information [Line Items]  
Entity Registrant Name BioMarin Pharmaceutical Inc
Entity Central Index Key 0001048477
v3.26.1
Pay vs Performance Disclosure - USD ($)
 1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2023
Nov. 30, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table    
Year
Summary
Compensation
Table Total
for PEO 1(1)
($)
Summary
Compensation
Table Total
for PEO 2(1)
($)
Compensation
Actually Paid
to PEO 1(1)(2)(3)
($)
Compensation
Actually Paid
to PEO 2(1)(2)(3)
($)
Average
Summary
Compensation
Table Total for
Non-PEO
NEOs(1)
($)
Average
Compensation
Actually Paid
to Non-PEO
NEOs(1)(2)(3)
($)
Value of Initial Fixed $100
Investment based on:(4)
GAAP Net
Income
(Loss)
($ Millions)
Total Revenues
($ Millions)(5)
TSR
($)
Peer Group
TSR
($)
2025— 21,927,563 — 12,209,116 6,352,943 3,731,035 67.77 124.75 348.9 3,221 
2024— 14,853,605 — 2,421,839 6,566,982 1,711,776 74.96 93.49 426.9 2,854 
202321,976,020 17,875,236 15,757,509 18,518,864 6,321,622 5,564,948 109.96 94.03 167.6 2,419 
202218,351,880 — 34,379,532 — 6,114,555 10,821,939 118.02 89.90 141.6 2,096 
202118,262,538 — 18,390,254 — 5,510,297 5,670,256 100.75 100.02 (64.1)1,846 
        
Company Selected Measure Name     Total Revenues        
Named Executive Officers, Footnote     Jean-Jacques Bienaimé was our PEO for each year presented until November 30, 2023 (PEO 1), and Alexander Hardy has been our PEO since December 1, 2023 (PEO 2). The individuals comprising the Non-PEO NEOs for each year presented are listed below.
20212022202320242025
Brian R. MuellerBrian R. MuellerBrian R. MuellerBrian R. MuellerBrian R. Mueller
Jeff AjerJeff AjerJeff AjerG. Eric DavisCristin Hubbard
Henry J. Fuchs, M.D.Henry J. Fuchs, M.D.Henry J. Fuchs, M.D.Henry J. Fuchs, M.D.
Gregory R. Friberg, M.D.
C. Greg Guyer, Ph.D.G. Eric DavisC. Greg Guyer, Ph.D.Cristin HubbardC. Greg Guyer, Ph.D.
Gregory R. Friberg, M.D.
        
Peer Group Issuers, Footnote     The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2025. The comparison assumes $100 was invested for the period starting December 31, 2020, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.        
PEO Total Compensation Amount     $ 21,927,563        
PEO Actually Paid Compensation Amount     $ 12,209,116        
Adjustment To PEO Compensation, Footnote     Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
YearSummary
Compensation
Table Total for
PEO 2
($)		Exclusion of
Stock Awards
and Option
Awards for
PEO 2
($)		Inclusion
of Equity
Values for
PEO 2
($)		Compensation
Actually Paid to
PEO 2
($)
202521,927,563 (18,742,939)9,024,492 12,209,116 
YearAverage
Summary
Compensation
Table Total for
Non-PEO NEOs
($)		Average
Exclusion of
Stock Awards
and Option
Awards for
Non-PEO NEOs
($)		Average
Inclusion of
Equity Values
for Non-PEO
NEOs
($)		Average
Compensation
Actually Paid to
Non-PEO NEOs
($)
20256,352,943 (5,062,936)2,441,028 3,731,035 
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of Year
for PEO 2
($)		Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards
for PEO 2
($)		Change in Fair
Value from Last
Day of Prior Year
to Vesting Date of
Unvested Equity
Awards that
Vested During
Year for PEO 2
($)		Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for PEO 2
($)		Total - Inclusion
of Equity Values
for PEO 2
($)
202511,098,209 (1,508,115)(565,602)— 9,024,492 
YearAverage Year-End
Fair Value of Equity
Awards Granted
During Year That
Remained Unvested
as of Last Day of Year
for Non-PEO NEOs
($)		Average Change in
Fair Value from
Last Day of Prior
Year to Last Day of
Year of Unvested
Equity Awards for
Non-PEO NEOs
($)		Average Change in
Fair Value from Last
Day of Prior Year to
Vesting Date of
Unvested Equity
Awards that Vested
During Year for
Non-PEO NEOs
($)		Average Fair
Value at Last Day
of Prior Year of
Equity Awards
Forfeited
During Year for
Non-PEO NEOs
($)		Total - Average
Inclusion of
Equity Values for
Non-PEO NEOs
($)
20252,991,701 (490,906)(59,767)— 2,441,028 
        
Non-PEO NEO Average Total Compensation Amount     $ 6,352,943 $ 6,566,982 $ 6,321,622 $ 6,114,555 $ 5,510,297
Non-PEO NEO Average Compensation Actually Paid Amount     $ 3,731,035 1,711,776 5,564,948 10,821,939 5,670,256
Adjustment to Non-PEO NEO Compensation Footnote     Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
YearSummary
Compensation
Table Total for
PEO 2
($)		Exclusion of
Stock Awards
and Option
Awards for
PEO 2
($)		Inclusion
of Equity
Values for
PEO 2
($)		Compensation
Actually Paid to
PEO 2
($)
202521,927,563 (18,742,939)9,024,492 12,209,116 
YearAverage
Summary
Compensation
Table Total for
Non-PEO NEOs
($)		Average
Exclusion of
Stock Awards
and Option
Awards for
Non-PEO NEOs
($)		Average
Inclusion of
Equity Values
for Non-PEO
NEOs
($)		Average
Compensation
Actually Paid to
Non-PEO NEOs
($)
20256,352,943 (5,062,936)2,441,028 3,731,035 
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
YearYear-End Fair
Value of Equity
Awards Granted
During Year
That Remained
Unvested as of
Last Day of Year
for PEO 2
($)		Change in Fair
Value from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards
for PEO 2
($)		Change in Fair
Value from Last
Day of Prior Year
to Vesting Date of
Unvested Equity
Awards that
Vested During
Year for PEO 2
($)		Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for PEO 2
($)		Total - Inclusion
of Equity Values
for PEO 2
($)
202511,098,209 (1,508,115)(565,602)— 9,024,492 
YearAverage Year-End
Fair Value of Equity
Awards Granted
During Year That
Remained Unvested
as of Last Day of Year
for Non-PEO NEOs
($)		Average Change in
Fair Value from
Last Day of Prior
Year to Last Day of
Year of Unvested
Equity Awards for
Non-PEO NEOs
($)		Average Change in
Fair Value from Last
Day of Prior Year to
Vesting Date of
Unvested Equity
Awards that Vested
During Year for
Non-PEO NEOs
($)		Average Fair
Value at Last Day
of Prior Year of
Equity Awards
Forfeited
During Year for
Non-PEO NEOs
($)		Total - Average
Inclusion of
Equity Values for
Non-PEO NEOs
($)
20252,991,701 (490,906)(59,767)— 2,441,028 
        
Compensation Actually Paid vs. Total Shareholder Return    
Description of Relationship Between Compensation Actually Paid, Company TSR, and Peer Group TSR
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the Nasdaq Biotechnology Index over the same period.
PEO and Average Non-PEO NEO Compensation Actually Paid Versus TSR
6635
 n
PEO 1 Compensation Actually Paid
 n 
PEO 2 Compensation Actually Paid
 n 
Average
Non-PEO NEO
Compensation
Actually Paid
  icon_legend.jpg  
BioMarin TSR
 02_427475-1_icon_legend_biomarin magenta.jpg  
Nasdaq Biotechnology Index TSR
        
Compensation Actually Paid vs. Net Income    
Description of Relationship Between Compensation Actually Paid and GAAP Net Income (Loss)
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our GAAP Net Income (Loss) during the five most recently completed fiscal years.
PEO and Average Non-PEO NEO Compensation Actually Paid Versus GAAP Net Income (Loss)
7058
 n
PEO 1 Compensation Actually Paid
 n 
PEO 2 Compensation Actually Paid
 n 
Average
Non-PEO NEO
Compensation
Actually Paid
 02_427475-1_icon_legend_biomarin magenta.jpg  
GAAP Net
Income (Loss)
        
Compensation Actually Paid vs. Company Selected Measure    
Description of Relationship Between Compensation Actually Paid and Total Revenues
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Total Revenue ($ in Millions) during the five most recently completed fiscal years.
PEO and Average Non-PEO NEO Compensation Actually Paid Versus Total Revenues
7472
 n
PEO 1 Compensation Actually Paid
 n 
PEO 2 Compensation Actually Paid
 n 
Average
Non-PEO NEO
Compensation
Actually Paid
 icon_legend.jpg  
Total Revenues
        
Total Shareholder Return Vs Peer Group    
Description of Relationship Between Compensation Actually Paid, Company TSR, and Peer Group TSR
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the Nasdaq Biotechnology Index over the same period.
PEO and Average Non-PEO NEO Compensation Actually Paid Versus TSR
6635
 n
PEO 1 Compensation Actually Paid
 n 
PEO 2 Compensation Actually Paid
 n 
Average
Non-PEO NEO
Compensation
Actually Paid
  icon_legend.jpg  
BioMarin TSR
 02_427475-1_icon_legend_biomarin magenta.jpg  
Nasdaq Biotechnology Index TSR
        
Tabular List, Table    
Total Revenues
Non-GAAP Diluted EPS
Relative TSR
Revenue CAGR
Core Operating Margin
Incremental Revenue Attained from New Products and Programs and/or the Acceleration of Existing Programs
Number of Product Regulatory Approvals by the FDA and EMA and IND/CTAs submitted to the FDA and EMA and Number of Development Programs that Achieve Proofs of Concept or Meet Clinical Milestones
        
Total Shareholder Return Amount     $ 67.77 74.96 109.96 118.02 100.75
Peer Group Total Shareholder Return Amount     124.75 93.49 94.03 89.90 100.02
Net Income (Loss)     $ 348,900,000 $ 426,900,000 $ 167,600,000 $ 141,600,000 $ (64,100,000)
Company Selected Measure Amount     3,221,000,000 2,854,000,000 2,419,000,000 2,096,000,000 1,846,000,000
PEO Name     Alexander Hardy Alexander Hardy      
Additional 402(v) Disclosure     The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
Tabular List of Most Important Financial and Non-Financial Performance Measures
The following table presents the financial and non-financial performance measures the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and Non-PEO NEOs for 2025 to Company performance. The measures in this table are not ranked.
All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference. 		       
Measure:: 1              
Pay vs Performance Disclosure              
Name     Total Revenues        
Non-GAAP Measure Description     We determined Total Revenues to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2025. This measure may not have been the most important financial performance measure for prior years, and we may determine a different financial performance measure to be the most important financial performance measure in future years.        
Measure:: 2              
Pay vs Performance Disclosure              
Name     Non-GAAP Diluted EPS        
Measure:: 3              
Pay vs Performance Disclosure              
Name     Relative TSR        
Measure:: 4              
Pay vs Performance Disclosure              
Name     Revenue CAGR        
Measure:: 5              
Pay vs Performance Disclosure              
Name     Core Operating Margin        
Measure:: 6              
Pay vs Performance Disclosure              
Name     Incremental Revenue Attained from New Products and Programs and/or the Acceleration of Existing Programs        
Measure:: 7              
Pay vs Performance Disclosure              
Name     Number of Product Regulatory Approvals by the FDA and EMA and IND/CTAs submitted to the FDA and EMA and Number of Development Programs that Achieve Proofs of Concept or Meet Clinical Milestones        
Alexander Hardy [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     $ 21,927,563 $ 14,853,605 $ 17,875,236    
PEO Actually Paid Compensation Amount     12,209,116 $ 2,421,839 18,518,864    
PEO Name Alexander Hardy            
Jean-Jacques Bienaimé [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount         21,976,020 $ 18,351,880 $ 18,262,538
PEO Actually Paid Compensation Amount         $ 15,757,509 $ 34,379,532 $ 18,390,254
PEO Name   Jean-Jacques Bienaimé       Jean-Jacques Bienaimé Jean-Jacques Bienaimé
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (18,742,939)        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     9,024,492        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     11,098,209        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,508,115)        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (565,602)        
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (5,062,936)        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     2,441,028        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     2,991,701        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (490,906)        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (59,767)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ 0        
v3.26.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2025
Award Timing Disclosures [Line Items]  
Award Timing MNPI Disclosure
The Compensation Committee generally approves and grants annual equity awards at approximately the same time every year as part of the company-wide performance review and compensation cycle. Typically, each year the Compensation Committee approves the dollar value of equity awards at a meeting held in late February or early March, shortly after the filing of our annual report on Form 10-K, for grant on or about March 15 of such year. Outside of the annual grant cycle, we may make equity awards in connection with new hire packages or retention grants. In the case of new hire awards, the grant date is typically the start date for our senior executives and on or about the 15th day of the month for non-executive employees. Also, non-employee directors receive automatic grants of initial equity awards at the time of a director’s initial appointment or election to the board and at the time of each year’s Annual Meeting of Stockholders, respectively, pursuant to our current director compensation policy. While there is no specific cadence with respect to retention grants given their ad hoc nature, such awards are not made in anticipation of the release of material nonpublic information. We have not timed the release of material nonpublic information for the purpose of affecting the value of executive compensation. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features.
All awards are granted under a stockholder-approved plan and stock options are granted at an exercise price at the closing market price of our common stock on the grant date. Equity awards, including options, are not granted in anticipation of the release of material non-public information, and the release of material nonpublic information is not timed on the basis of option or equity grant dates.
Award Timing Method Outside of the annual grant cycle, we may make equity awards in connection with new hire packages or retention grants. In the case of new hire awards, the grant date is typically the start date for our senior executives and on or about the 15th day of the month for non-executive employees. Also, non-employee directors receive automatic grants of initial equity awards at the time of a director’s initial appointment or election to the board and at the time of each year’s Annual Meeting of Stockholders, respectively, pursuant to our current director compensation policy. While there is no specific cadence with respect to retention grants given their ad hoc nature, such awards are not made in anticipation of the release of material nonpublic information.
Award Timing Predetermined true
Award Timing MNPI Considered false
Award Timing, How MNPI Considered We have not timed the release of material nonpublic information for the purpose of affecting the value of executive compensation. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features.All awards are granted under a stockholder-approved plan and stock options are granted at an exercise price at the closing market price of our common stock on the grant date. Equity awards, including options, are not granted in anticipation of the release of material non-public information, and the release of material nonpublic information is not timed on the basis of option or equity grant dates.
MNPI Disclosure Timed for Compensation Value false
v3.26.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true